Home Financial Reports and Presentations Key data from Phase II…

On April 4, 2016, top line results from the ongoing Phase II clinical trial with our lead product ATIR101™, were presented in an oral presentation and two poster presentations at EBMT. This is the slide deck of the oral presentation.

Download (PDF, 1.2MB)